CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development
TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ —CytoReason, a leading developer of computational disease models for efficient drug discovery and development, today announced the extension of its collaboration agreement with Pfizer. “The...